Drugging the R-loop interactome: RNA-DNA hybrid binding proteins as targets for cancer therapy

Beáta Boros-Oláh, Nikoletta Dobos, Lilla Hornyák, Z. Szabó, Z. Karányi, Gábor Halmos, Jason Roszik, Lóránt Székvölgyi

Research output: Article

Abstract

Unravelling the origin of genetic alterations from point mutations to chromosomal rearrangements was greatly enhanced by the discovery of RNA-DNA hybrids (R-loops) that behave as hotspots of genomic instability in a variety of organisms. Current models suggest that uncontrolled R-loops are a hazard to genome integrity, therefore, identifying proteins that are involved in recognising and signalling R-loop structures are of key importance. Herein we analysed key RNA-DNA hybrid binding proteins in humans taking advantage of large-scale gene expression, survival rate, and drug-sensitivity data from cancer genomics databases. We show that expression of RNA-DNA hybrid binding proteins in various cancer types is associated with survival and may have contrasting outcomes in responding to therapeutic treatments. Based on the revealed pharmacogenomic landscape of human RNA-DNA hybrid binding proteins, we propose that R-loops and R-loop binding proteins are potentially relevant new epigenetic markers and therapeutic targets in multiple cancers.

Original languageEnglish
Article number102642
JournalDNA Repair
DOIs
Publication statusPublished - jan. 1 2019

Fingerprint

DNA-Binding Proteins
Carrier Proteins
RNA
DNA
Neoplasms
Genomic Instability
Pharmacogenetics
Therapeutics
Genomics
Point Mutation
Epigenomics
Gene expression
Hazards
Genes
Genome
Databases
Gene Expression
Survival
Pharmaceutical Preparations
Proteins

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Drugging the R-loop interactome : RNA-DNA hybrid binding proteins as targets for cancer therapy. / Boros-Oláh, Beáta; Dobos, Nikoletta; Hornyák, Lilla; Szabó, Z.; Karányi, Z.; Halmos, Gábor; Roszik, Jason; Székvölgyi, Lóránt.

In: DNA Repair, 01.01.2019.

Research output: Article

Boros-Oláh, Beáta ; Dobos, Nikoletta ; Hornyák, Lilla ; Szabó, Z. ; Karányi, Z. ; Halmos, Gábor ; Roszik, Jason ; Székvölgyi, Lóránt. / Drugging the R-loop interactome : RNA-DNA hybrid binding proteins as targets for cancer therapy. In: DNA Repair. 2019.
@article{e5abc6c7a37d429a83eb86e0bdaa41d8,
title = "Drugging the R-loop interactome: RNA-DNA hybrid binding proteins as targets for cancer therapy",
abstract = "Unravelling the origin of genetic alterations from point mutations to chromosomal rearrangements was greatly enhanced by the discovery of RNA-DNA hybrids (R-loops) that behave as hotspots of genomic instability in a variety of organisms. Current models suggest that uncontrolled R-loops are a hazard to genome integrity, therefore, identifying proteins that are involved in recognising and signalling R-loop structures are of key importance. Herein we analysed key RNA-DNA hybrid binding proteins in humans taking advantage of large-scale gene expression, survival rate, and drug-sensitivity data from cancer genomics databases. We show that expression of RNA-DNA hybrid binding proteins in various cancer types is associated with survival and may have contrasting outcomes in responding to therapeutic treatments. Based on the revealed pharmacogenomic landscape of human RNA-DNA hybrid binding proteins, we propose that R-loops and R-loop binding proteins are potentially relevant new epigenetic markers and therapeutic targets in multiple cancers.",
keywords = "Cancer diagnostics and therapy, Chemotherapy, Clinical trial, Drug sensitivity, R-loop, RNA-DNA hybrid, Survival association",
author = "Be{\'a}ta Boros-Ol{\'a}h and Nikoletta Dobos and Lilla Horny{\'a}k and Z. Szab{\'o} and Z. Kar{\'a}nyi and G{\'a}bor Halmos and Jason Roszik and L{\'o}r{\'a}nt Sz{\'e}kv{\"o}lgyi",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.dnarep.2019.102642",
language = "English",
journal = "DNA Repair",
issn = "1568-7864",
publisher = "Elsevier",

}

TY - JOUR

T1 - Drugging the R-loop interactome

T2 - RNA-DNA hybrid binding proteins as targets for cancer therapy

AU - Boros-Oláh, Beáta

AU - Dobos, Nikoletta

AU - Hornyák, Lilla

AU - Szabó, Z.

AU - Karányi, Z.

AU - Halmos, Gábor

AU - Roszik, Jason

AU - Székvölgyi, Lóránt

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Unravelling the origin of genetic alterations from point mutations to chromosomal rearrangements was greatly enhanced by the discovery of RNA-DNA hybrids (R-loops) that behave as hotspots of genomic instability in a variety of organisms. Current models suggest that uncontrolled R-loops are a hazard to genome integrity, therefore, identifying proteins that are involved in recognising and signalling R-loop structures are of key importance. Herein we analysed key RNA-DNA hybrid binding proteins in humans taking advantage of large-scale gene expression, survival rate, and drug-sensitivity data from cancer genomics databases. We show that expression of RNA-DNA hybrid binding proteins in various cancer types is associated with survival and may have contrasting outcomes in responding to therapeutic treatments. Based on the revealed pharmacogenomic landscape of human RNA-DNA hybrid binding proteins, we propose that R-loops and R-loop binding proteins are potentially relevant new epigenetic markers and therapeutic targets in multiple cancers.

AB - Unravelling the origin of genetic alterations from point mutations to chromosomal rearrangements was greatly enhanced by the discovery of RNA-DNA hybrids (R-loops) that behave as hotspots of genomic instability in a variety of organisms. Current models suggest that uncontrolled R-loops are a hazard to genome integrity, therefore, identifying proteins that are involved in recognising and signalling R-loop structures are of key importance. Herein we analysed key RNA-DNA hybrid binding proteins in humans taking advantage of large-scale gene expression, survival rate, and drug-sensitivity data from cancer genomics databases. We show that expression of RNA-DNA hybrid binding proteins in various cancer types is associated with survival and may have contrasting outcomes in responding to therapeutic treatments. Based on the revealed pharmacogenomic landscape of human RNA-DNA hybrid binding proteins, we propose that R-loops and R-loop binding proteins are potentially relevant new epigenetic markers and therapeutic targets in multiple cancers.

KW - Cancer diagnostics and therapy

KW - Chemotherapy

KW - Clinical trial

KW - Drug sensitivity

KW - R-loop

KW - RNA-DNA hybrid

KW - Survival association

UR - http://www.scopus.com/inward/record.url?scp=85068486502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068486502&partnerID=8YFLogxK

U2 - 10.1016/j.dnarep.2019.102642

DO - 10.1016/j.dnarep.2019.102642

M3 - Article

AN - SCOPUS:85068486502

JO - DNA Repair

JF - DNA Repair

SN - 1568-7864

M1 - 102642

ER -